<DOC>
	<DOC>NCT02805244</DOC>
	<brief_summary>A mass balance study to determine the routes and rates of elimination of radioactivity, to determine total radioactivity in plasma and whole blood over time and compare levels to JTZ-951 and drug-derived entities in plasma and to determine pharmacokinetic (PK) parameters of JTZ-951 and its metabolite(s).</brief_summary>
	<brief_title>Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>Subjects with end stage renal disease on hemodialysis Postdialysis body weight &gt;45.0 kg BMI between 18.0 and 40.0 kg/m2 (inclusive) Subjects with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.0 × upper limit of normal (ULN), or total bilirubin &gt;1.5 × ULN at the Screening Visit Subjects who have hepatobiliary disease or condition (such as biliary cirrhosis) Subjects with positive test results for HBsAg (hepatitis B surface antigen), HCV antibody or HIV antibody Subjects with known history of liver failure or liver surgery Subjects with a history or current clinically significant chronic or acute blood loss</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>JTZ-951</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>14C-JTZ-951</keyword>
	<keyword>Mass balance</keyword>
	<keyword>Time course</keyword>
</DOC>